The economic potential of smoking cessation interventions at the point of diagnosis of non-small-cell lung cancer (NSCLC).

TL;DR: By reducing smoking rates, healthcare systems can more efficiently allocate resources, enhance patient health outcomes, and lessen the overall cancer burden.

TL;DR: Quitting smoking is independently and significantly associated with improved survival regardless of stage in NSCLC and it is recommended that smoking cessation advice and treatments should be offered to smokers with lung cancer.

TL;DR: Smoking cessation and low-dose CT screening are effective interventions for reducing lung cancer mortality. Combining both interventions can save even more lives.

TL;DR: Smoking imposes a heavy economic burden throughout the world, particularly in Europe and North America, where the tobacco epidemic is most advanced, and the urgent need for countries to implement stronger tobacco control measures to address these costs is highlighted.

TL;DR: A review of the evidence from Cochrane Reviews that assessed the effect of behavioural interventions designed to support smoking cessation attempts to address the following two questions: How do modes of delivery, person delivering the intervention, and the behavioural and motivational components of behavioural intervention for smoking cessation compare with each other in achieving abstinence at follow-up of six months or longer.

TL;DR: This is the first comprehensive study describing the burden of illness for patients with completely resected stage IB-IIIA NSCLC and the economic burden was substantial in all three countries.

TL;DR: A smoking cessation program initiated before surgical lung resection is cost-effective at both 1 and 5 years postsurgery, and providers should encourage patients who are still smoking to engage in formal smoking cessation programs.